Colchicine in patients with chronic inflammatory cardiomyopathy: Rationale and design of the CMP-MYTHiC - PubMed
5 hours ago
- #inflammatory cardiomyopathy
- #clinical trial
- #colchicine
- The CMP-MYTHiC trial evaluates colchicine's efficacy in reducing myocardial inflammation in chronic inflammatory cardiomyopathy (Infl-CMP) patients.
- Infl-CMP, diagnosed via CMRI or FDG-PET, increases risks of ventricular arrhythmias (VA), left ventricular systolic dysfunction (LVSD), and heart failure (HF).
- Eligibility includes adult patients with VA or LVSD/HF phenotypes, excluding those with myocardial infarction, other cardiomyopathies, or autoimmune disorders.
- Primary endpoint assesses clinical, arrhythmic, and imaging improvements at 6 months, comparing colchicine to placebo.
- The trial aims for 80% power, requiring 40 patients per group, with results expected by 2029.